Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Subjects With Chronic Kidney Disease (CKD), Stages 3 and 4
Status:
Completed
Trial end date:
2010-09-24
Target enrollment:
Participant gender:
Summary
This study was conducted to assess the pharmacokinetic (PK) profile, safety, and tolerability
in participants with Stage 3 and 4 Chronic Kidney Disease (CKD) following a single oral dose
of vadadustat.